ClinicalTrials.gg

Program

rulonilimab

Also written as “F520”, “F520 combined with chemotherapy” and “Rulonilimab”.

Its studies are mostly in Neoplasms, Unknown Primary · Uterine Cervical Neoplasms · Carcinoma, Hepatocellular · Carcinoma, Non-Small-Cell Lung · Lymphoma, T-Cell, Peripheral, led by Lunan Pharmaceutical Group.

Furthest: phase 3, since Jun 2, 20229 company-led studies, 3 open or runningNext primary completion: Dec 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lunan Pharmaceutical Group93 open or runningphase 3since Jun 2, 2022Jul 1, 2020Dec 30, 2027phase 3 · NCT07761429

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 1, 2020First studies: 2 phase 2 studiesFirst studyNCT04457869, NCT04457830
  2. Nov 18, 2020Phase 2 study in Locally Advanced or Metastatic Urothelial Cell CarcinomaNCT04636515 · 80 enrolled
  3. Dec 17, 2021Phase 2 study in Parkinson Disease 4, Autosomal Dominant Lewy BodyNCT05178836 · 62 enrolled
  4. Jun 2, 2022Phase 3 study in Carcinoma, HepatocellularNCT05408221 · 576 planned · China
  5. Feb 3, 20232 phase 2 studiesNCT05740215, NCT05741021
  6. Dec 24, 2024Phase 3 study in Uterine Cervical NeoplasmsNCT06755515 · 510 planned · China
  7. May 27, 2026Phase 3 study in Neoplasms, Unknown PrimaryNCT07761429 · 402 planned · China

Ahead

  1. Dec 30, 2027Primary completion: phase 3 study in Neoplasms, Unknown PrimaryNCT07761429
  2. Sep 2028Primary completion: phase 3 study in Uterine Cervical NeoplasmsNCT06755515

TargetBeta

PDCD1 →read by rule
“A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34
sasanlimabPfizerphase 34

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07761429Neoplasms, Unknown Primary · China3RecruitingDec 30, 2027402
NCT06755515Uterine Cervical Neoplasms · China3By invitationSep 2028510
NCT05741021Carcinoma, Non-Small-Cell Lung · China2UNKNOWNOct 25, 202484
NCT05740215Solid Tumors · China2UNKNOWNMay 22, 2024158
NCT05408221Carcinoma, Hepatocellular · China3RecruitingAug 1, 2025576
NCT05178836Parkinson Disease 4, Autosomal Dominant Lewy Body2UNKNOWNDec 31, 202362
NCT04636515Locally Advanced or Metastatic Urothelial Cell Carcinoma2UNKNOWNMar 202280
NCT04457869Primary Central Nervous System Lymphoma2UNKNOWNJul 31, 202243
NCT04457830Lymphoma, T-Cell, Peripheral2UNKNOWNJul 31, 2022105

How it is read

Names in the registry

  • “F520”, 5 entries
  • “F520 combined with chemotherapy”, 1 entry
  • “Rulonilimab”, 1 entry
  • “Rulonilimab+Lenvatinib”, 1 entry
  • “F520+F007”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.